Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT.
OBJECTIVE
The aims of this study were to determine the distribution of serum alanine aminotransferase levels in a normal population and to clarify whether interferon treatment is justified in HCV-infected patients with persistently normal alanine aminotransferase levels.


METHODS
The distribution of alanine aminotransferase levels was examined among 949 normal subjects who were negative for hepatitis viruses, denied regular alcohol use. Nineteen patients with chronic hepatitis C and persistently normal alanine aminotransferase levels were treated with alpha interferon (six or ten million units thrice weekly for six months).


RESULTS
Peaks of alanine aminotransferase distribution among the normal subjects were seen at 16-20 IU/L and 11-15 IU/L in males and females, respectively. Fourteen of the 19 patients who received interferon treatment had favorable factors of response to interferon (eight with low pretreatment virus load, four with HCV genotype 2 and two with both). A sustained virological response was achieved in eight (57%) of 14, and alanine aminotransferase levels decreased significantly to within the normal range after interferon treatment in six of eight.


CONCLUSIONS
Patients with chronic hepatitis C and persistently normal alanine aminotransferase levels should be treated with high doses of interferon if they have favorable factors of response to interferon treatment.
Sakugawa
Hiroshi
H
First Department of Internal Medicine, University Hospital, Faculty of Medicine, University of the Ryukyus, 207 Uehara, Okinawa, Japan. b987607@med.u-ryukyu.ac.jp
Nakasone
Hiroki
H
Nakayoshi
Tomofumi
T
Kawakami
Yuko
Y
Yamashiro
Tsuyoshi
T
Maeshiro
Tatsuji
T
Kinjo
Fukunori
F
Saito
Atsushi
A
Yakabi
Shizuko
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000410:Alanine Transaminase / Q000097:blood* / Q000187:drug effects*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000209:etiology / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005260:Female; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000097:blood* / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D012720:Severity of Illness Index; D013997:Time Factors; D019562:Viral Load
D000998:Antiviral Agents; D016898:Interferon-alpha; D000410:Alanine Transaminase